10 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 9 Phase 2, 7 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 7 | Completed 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 4 | 1 | Completed 1 |
Follow RNA, Messenger: new trials by email Literature Review of RNA, Messenger trials Research Report on RNA, Messenger
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Acne mRNA (messenger ribonucleic acid) vaccine, Placebo - Acne | Phase 2 | Not yet recruiting | Sanofi | 410 | 2026-10-30 | 2026-09-18 |
| A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2 - Influenza, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1162 | 2025-01-06 | 2026-06-09 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) Part1:Recombinant two-component COVID-19 vaccine (CHO cell), Part1: Placebo, Part2: Recombinant two-component COVID-19 vaccine (CHO cell) - COVID-19 | Phase 2 | Completed | Jiangsu Rec-Biotechnology Co., Ltd. | 948 | 2022-01-31 | 2024-02-29 |
| Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction Tozinameran - COVID-19, Vaccine Reaction | Phase 4 | Completed | Murdoch Childrens Research Institute | 51 | 2022-01-20 | 2023-02-09 |
| COVID-19 Protection After Transplant Pilot Study BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna) - Kidney Transplant Recipients | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 81 | 2021-08-10 | 2025-07-30 |
| Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines - COVID-19 Pandemic, SARS-CoV2 Infection | Completed | Hacettepe University | 1223 | 2021-06-21 | 2024-02-28 | |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN kidney transplantation - Kidney Transplant Rejection, Kidney Transplantation | Completed | Assistance Publique - Hôpitaux de Paris | 558 | 2018-11-27 | 2024-06-05 | |
| Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients TriMix_100, TriMix_300, 600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA) - HIV-infection | Phase 1 | Completed | Judit Pich Martínez | 21 | 2015-06-01 | 2025-08-22 |
| A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection - HIV-1 Infection, HIV Infections | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 15 | 2009-08-01 | 2016-03-08 |
| Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients autologous dendritic cells electroporated with mRNA - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Radboud University Medical Center | 23 | 2009-06-01 | 2018-12-07 |
| Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients mRNA, GM-CSF s.c. - Malignant Melanoma | Phase 1 / Phase 2 | Completed | University Hospital Tuebingen | 20 | 2004-07-01 | 2007-04-19 |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy Peptide vaccine, Montanide ISA-51, Granulocyte macrophage colony stimulating factor (GM-CSF) - Recurrent Prostate Cancer | Phase 1 / Phase 2 | Unknown | University Hospital Tuebingen | 36 | 2004-04-01 | 2017-08-17 |
COVID-19 (3) · Infections (2) · Acne Vulgaris (1) · Acquired Immunodeficiency Syndrome (1) · HIV Infections (1) · Hemangiosarcoma (1) · Hematologic Neoplasms (1) · Influenza, Human (1) · Leukemia (1) · Lymphoma (1) · Melanoma (1) · Multiple Myeloma (1) · Prostatic Neoplasms (1) · Rejection, Psychology (1) · Uveal Melanoma (1)
University Hospital Tuebingen (2) · Assistance Publique - Hôpitaux de Paris (1) · Hacettepe University (1) · Jiangsu Rec-Biotechnology Co., Ltd. (1) · Judit Pich Martínez (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Murdoch Childrens Research Institute (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Radboud University Medical Center (1) · Sanofi (1) · Sanofi Pasteur, a Sanofi Company (1)
United States (4) · Australia (2) · Germany (2) · Spain (2) · France (1) · Netherlands (1) · Philippines (1) · Switzerland (1) · Turkey (Türkiye) (1)
Alexandre Loupy, Pr (1) · Arnulf Stenzl, Prof. (1) · Banu Cakir (1) · Claus Garbe, Prof. Dr. (1) · Cornelis JA Punt, prof.MD (1) · Dorry L. Segev, MD, PhD (1) · James Gulley, M.D. (1) · Nigel Curtis (1) · Rajesh Gandhi, MD (1) · Vinod Ravi, MD (1)
PMID 19609242, PMID 30289805, PMID 31165086, PMID 34206047, PMID 34889882, PMID 34928943, PMID 35205759, PMID 35366507, PMID 36366011, PMID 36412095, PMID 3641838, PMID 36418380, PMID 36966905, PMID 36990211, PMID 37142762, PMID 37180729, PMID 37261286, PMID 37265662, PMID 38019656, PMID 38103161, PMID 38529685
2014 (1), R01AI066992 (1)